Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
NCT ID: NCT06984887
Last Updated: 2026-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
6100 participants
INTERVENTIONAL
2025-12-19
2026-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What are the sensitivity and specificity of the new diagnostic tests Pluslife MTBC and Ustar PortNAT for tuberculosis and how do these compare to Xpert Ultra?
* How does the new diagnostic method compare to Xpert Ultra in terms of implementation feasibility, cost and turnaround time?
* What are the logistical and technical advantages and challenges associated with implementing the new diagnostic method compared to Xpert Ultra?
* What are the perceptions of healthcare providers as well as sample provider regarding the usability, feasibility and convenience of use of the new sample collection method compared to existing methods?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons
NCT02538952
Sensitivity and Specificity of Xpert MTB/RIF Ultra
NCT06058065
Study of GeneXpert Mycobacterium Tuberculosis/ Rifampicin (MTB/RIF) Versus the Routine Methods for Detection of Mycobacterium Tuberculosis
NCT06409572
Trial of Point-of-treatment Xpert MTB/RIF Assay
NCT01554384
Acceptability and Feasibility of Home-based TB Testing
NCT04973371
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study aims to assess the diagnostic accuracy-specifically the sensitivity and specificity-of two new NAT-based tuberculosis (TB) tests, Pluslife and Ustar. These tests will be compared against the existing reference standard, the Xpert MTB/Rif Ultra, with culture testing used as the gold standard. This evaluation will take place in the context of Active Case Finding (ACF) in Pakistan. The research will follow a non-inferiority diagnostic trial design. The procedure involves testing all samples with cultures and comparing the results from the new NAT tests against the reference to determine their effectiveness in detecting and diagnosing TB.
Expected Outcomes:
Sensitivity of the new NAT tests Specificity of the new NAT tests False positive rate False negative rate
Research Objective 2:
This objective focuses on evaluating the operational feasibility, cost-effectiveness, and turnaround time of the new NAT diagnostics compared to the Xpert Ultra platform. The strategy will involve both quantitative and qualitative research methods. Quantitative data will be collected and analyzed regarding the cost per test and the time taken from sample receipt to result reporting. In addition, a qualitative study will be conducted using semi-structured in-depth interviews with presumptive TB patients and healthcare providers involved in sample collection at ACF camp settings. These interviews will explore experiences, challenges, and preferences related to the use of sputum samples versus tongue swabs.
Expected Outcomes:
Cost per test performed Average turnaround time for each NAT platform Preferences of sample providers regarding collection methods Preferences of healthcare providers regarding sample collection methods Specific challenges associated with each collection method Barriers to compliance with sample collection Overall feasibility and ease of use of the diagnostic approaches
Research Objective 3:
The third objective seeks to assess the acceptability and usability of tongue swab-based sample collection compared to traditional sputum sample methods. This will be explored through a qualitative inquiry, gathering in-depth insights from both sample providers and healthcare workers to understand their perspectives, experiences, and any usability issues associated with each method.
Expected Outcomes:
Insights into user and provider acceptance of tongue swab versus sputum collection Identification of usability challenges and practical considerations in sample collection methods
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
The aim of this trial is not to prove that the new test is better, but to show that the performance of the new tests is comparable to the current test which is used in ACF settings in Pakistan. The two new, the reference diagnostic test (Xpert Ultra) and the gold standard test (MTB culture) will be done in parallel to allow for a direct comparison of the two new tests and the reference test, performed on the same set of samples from each participant. This diagnostic evaluation study is cross-sectional in nature as it will typically involve assessing a diagnostic test's performance (such as sensitivity, specificity, etc.) at a single point in time. The key outcomes will be assessed using culture-confirmed TB and culture negative TB as a reference standard.
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic Trial
Diagnostic procedures
This study will be evaluated by conducting a non-inferiority diagnostic trial within routine ACF settings by comparing the New Diagnostic tests (NAT) to the reference standard test (Xpert MTB/Rif Assay) to determine how well it can detect and diagnose TB. All samples will be tested for MTB using cultures.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Diagnostic procedures
This study will be evaluated by conducting a non-inferiority diagnostic trial within routine ACF settings by comparing the New Diagnostic tests (NAT) to the reference standard test (Xpert MTB/Rif Assay) to determine how well it can detect and diagnose TB. All samples will be tested for MTB using cultures.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age range appropriate for the test (e.g., adult patients 12 yrs old and above)
* Any gender
* Consent to participate in the study and provide samples (e.g., tongue swab, sputum).
Exclusion Criteria
* Known cases of Pulmonary TB
* People who are unable to produce sputum
* Extra Pulmonary TB cases
* People who are not screened for TB on X-ray and/or their CAD scores are not available
12 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre for Global Public Health Pakistan
OTHER
Royal Tropical Institute
OTHER
Mercy Corps Pakistan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Reference Laboratory
Islamabad, Federal Capital, Pakistan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INV-045723
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.